Comparative Pharmacology
Head-to-head clinical analysis: BECLOVENT versus PULMICORT RESPULES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BECLOVENT versus PULMICORT RESPULES.
BECLOVENT vs PULMICORT RESPULES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; inhibits inflammatory mediators, reduces airway hyperresponsiveness, and suppresses immune cell activity.
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
2 inhalations (84 mcg) twice daily; not to exceed 10 inhalations (420 mcg) per day. Administered via oral inhalation using a metered-dose inhaler.
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
None Documented
None Documented
Terminal elimination half-life of beclomethasone dipropionate is 0.5 hours; active metabolite beclomethasone-17-monopropionate has half-life of 2.7 hours; clinically, systemic effects persist for 12-24 hours.
Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (60-70%) and urine (10-15%); less than 5% unchanged drug in urine.
Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid